ReviewCureus2026
Large-Cell Neuroendocrine Carcinoma of the Ampulla of Vater: A Systematic Literature Review of a Rare and Aggressive Entity.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine carcinomas of the ampulla of Vater are rare but highly aggressive, poorly differentiated neoplasms associated with poor outcomes. This contrasts with ampullary adenocarcinoma, which is generally associated with more favourable survival following curative resection, and with well-differentiated periampullary neuroendocrine tumours, which typically demonstrate more indolent behaviour and better prognosis. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-compliant systematic review was conducted across PubMed/MEDLINE, Embase, Scopus, Web of Science, and Google Scholar (from inception to July 2025) to identify reported cases of large-cell neuroendocrine carcinoma (LCNEC) of the ampulla of Vater. Studies reporting extractable patient-level clinicopathological, treatment, and outcome data were included. Data were standardised and synthesised descriptively due to the rarity and heterogeneity of the condition. A total of 22 patient-level cases of LCNEC of the ampulla of Vater were identified from 14 studies. The median age was 70 years (range: 44-84), with a male predominance. Tumours were generally small at presentation (median size approximately 20 mm); however, lymph node metastasis was present in 16 of 20 evaluable patients (80%). All patients underwent pancreaticoduodenectomy or pylorus-preserving pancreaticoduodenectomy. Adjuvant chemotherapy was administered in 12 of 22 patients (55%), most commonly platinum-based regimens. Tumour recurrence occurred in approximately 55-60% of cases, most frequently involving the liver. Median overall survival was approximately 11 months, with eight patients (36%) alive at the last follow-up. LCNEC of the ampulla of Vater is an aggressive malignancy with poor prognosis despite surgical resection. This review highlights a clinically important "size-biology paradox," whereby relatively small tumours demonstrate early metastatic behaviour and adverse outcomes. Tumour biology appears to outweigh conventional staging parameters, underscoring the need for early recognition, accurate histopathological classification, and consideration of systemic therapy. Further multicentre studies are required to optimise management strategies and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.